These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
360 related articles for article (PubMed ID: 28429168)
21. Population implications of the use of bedaquiline in people with extensively drug-resistant tuberculosis: are fears of resistance justified? Kunkel A; Furin J; Cohen T Lancet Infect Dis; 2017 Dec; 17(12):e429-e433. PubMed ID: 28533094 [TBL] [Abstract][Full Text] [Related]
22. Verapamil increases the bactericidal activity of bedaquiline against Mycobacterium tuberculosis in a mouse model. Gupta S; Tyagi S; Bishai WR Antimicrob Agents Chemother; 2015 Jan; 59(1):673-6. PubMed ID: 25331694 [TBL] [Abstract][Full Text] [Related]
23. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran. Velayati AA; Masjedi MR; Farnia P; Tabarsi P; Ghanavi J; ZiaZarifi AH; Hoffner SE Chest; 2009 Aug; 136(2):420-425. PubMed ID: 19349380 [TBL] [Abstract][Full Text] [Related]
24. TMC207 becomes bedaquiline, a new anti-TB drug. Palomino JC; Martin A Future Microbiol; 2013 Sep; 8(9):1071-80. PubMed ID: 24020736 [TBL] [Abstract][Full Text] [Related]
25. Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls. Kakkar AK; Dahiya N Tuberculosis (Edinb); 2014 Jul; 94(4):357-62. PubMed ID: 24841672 [TBL] [Abstract][Full Text] [Related]
26. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Pym AS; Diacon AH; Tang SJ; Conradie F; Danilovits M; Chuchottaworn C; Vasilyeva I; Andries K; Bakare N; De Marez T; Haxaire-Theeuwes M; Lounis N; Meyvisch P; Van Baelen B; van Heeswijk RP; Dannemann B; Eur Respir J; 2016 Feb; 47(2):564-74. PubMed ID: 26647431 [TBL] [Abstract][Full Text] [Related]
27. Bedaquiline: Current status and future perspectives. Khoshnood S; Goudarzi M; Taki E; Darbandi A; Kouhsari E; Heidary M; Motahar M; Moradi M; Bazyar H J Glob Antimicrob Resist; 2021 Jun; 25():48-59. PubMed ID: 33684606 [TBL] [Abstract][Full Text] [Related]
28. Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis. Xu J; Wang B; Hu M; Huo F; Guo S; Jing W; Nuermberger E; Lu Y Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320727 [TBL] [Abstract][Full Text] [Related]
29. Bedaquiline: An Insight Into its Clinical Use in Multidrug-Resistant Pulmonary Tuberculosis. Ahmad A; Akhtar J; Ahmad M; Khan MI; Wasim R; Islam A; Singh A Drug Res (Stuttg); 2024 Jul; 74(6):269-279. PubMed ID: 38968950 [TBL] [Abstract][Full Text] [Related]
30. Additional drug resistance of multidrug-resistant tuberculosis in patients in 9 countries. Kurbatova EV; Dalton T; Ershova J; Tupasi T; Caoili JC; Van Der Walt M; Kvasnovsky C; Yagui M; Bayona J; Contreras C; Leimane V; Via LE; Kim H; Akksilp S; Kazennyy BY; Volchenkov GV; Jou R; Kliiman K; Demikhova OV; Cegielski JP Emerg Infect Dis; 2015 Jun; 21(6):977-83. PubMed ID: 25988299 [TBL] [Abstract][Full Text] [Related]
31. No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis. Pang Y; Jing W; Lu J; Zong Z; Huo F; Dong L; Dai G; Li Y; Huang H; Chu N Diagn Microbiol Infect Dis; 2019 Aug; 94(4):361-364. PubMed ID: 30876684 [TBL] [Abstract][Full Text] [Related]
32. Extensively drug-resistant tuberculosis: early access to bedaquiline for a UK patient. van Halsema C; Humphreys S; Bonington A Eur Respir J; 2014 Jan; 43(1):292-4. PubMed ID: 23988770 [No Abstract] [Full Text] [Related]
33. High Prevalence of Bedaquiline Resistance in Treatment-Naive Tuberculosis Patients and Verapamil Effectiveness. Ghajavand H; Kargarpour Kamakoli M; Khanipour S; Pourazar Dizaji S; Masoumi M; Rahimi Jamnani F; Fateh A; Siadat SD; Vaziri F Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30602521 [TBL] [Abstract][Full Text] [Related]
34. Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST. Keller PM; Hömke R; Ritter C; Valsesia G; Bloemberg GV; Böttger EC Antimicrob Agents Chemother; 2015 Jul; 59(7):4352-5. PubMed ID: 25941226 [TBL] [Abstract][Full Text] [Related]
35. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline. Villellas C; Coeck N; Meehan CJ; Lounis N; de Jong B; Rigouts L; Andries K J Antimicrob Chemother; 2017 Mar; 72(3):684-690. PubMed ID: 28031270 [TBL] [Abstract][Full Text] [Related]
36. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. Tiberi S; De Lorenzo S; Centis R; Viggiani P; D'Ambrosio L; Migliori GB Eur Respir J; 2014 Jan; 43(1):289-92. PubMed ID: 23988772 [No Abstract] [Full Text] [Related]
37. Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers. Alffenaar JC; Akkerman OW; Anthony RM; Tiberi S; Heysell S; Grobusch MP; Cobelens FG; Van Soolingen D Expert Rev Anti Infect Ther; 2017 Jan; 15(1):11-21. PubMed ID: 27762157 [TBL] [Abstract][Full Text] [Related]
38. Initial experience of bedaquiline use in a series of drug-resistant tuberculosis patients from India. Udwadia ZF; Amale RA; Mullerpattan JB Int J Tuberc Lung Dis; 2014 Nov; 18(11):1315-8. PubMed ID: 25299863 [TBL] [Abstract][Full Text] [Related]
39. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. Tadolini M; Lingtsang RD; Tiberi S; Enwerem M; D'Ambrosio L; Sadutshang TD; Centis R; Migliori GB Eur Respir J; 2016 Sep; 48(3):935-8. PubMed ID: 27288039 [TBL] [Abstract][Full Text] [Related]
40. Bedaquiline: a new hope to treat multi-drug resistant tuberculosis. Patel RV; Riyaz SD; Park SW Curr Top Med Chem; 2014; 14(16):1866-74. PubMed ID: 25262806 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]